Cancer stem cell properties play critical roles in tumorigenesis, progression, and therapy, and SRg3 inhibits self-renewal activity in breast stem-like cancer cells by blocking Akt-induced HIF-1α activation and inhibiting HIF-1α-regulated expression of Bmi-1 and Sox-2 (Oh et al., 2019). The gene discussed is SOX2; the disease is cancer.